Paradigm Biopharma is continuing to progress the regulatory review of its novel treatment for conditions including osteoarthritis and Mucopolysaccharidosis.
The company is developing an injectable iPPS treatment for diseases where inflammation plays a major pathogenic role.
The late stage drug development company is working towards a Phase 3 clinical trial of its iPPS treatment.